Regulatory information

Registrations for AmGraft® in Singapore and Indonesia, the product documents, and how to report an adverse event.

Singapore Regulatory record

RegulatorHealth Sciences Authority (HSA)
CategoryClass 1 cell, tissue or gene therapy product (CTGTP)
NotificationHSA notification CTGT0041N, held by the manufacturer, Ventas Bio Pte Ltd
ManufacturerVentas Bio Pte Ltd, 2 Tukang Innovation Grove #07-02, JTC Medtech Hub, Singapore 618305
Distributor and exporterSanté Maison Pte. Ltd., UEN 202440255D

HSA requires suppliers of Class 1 CTGTP to submit a product notification and receive HSA’s written acceptance before supplying the product in Singapore. Class 1 CTGTP are currently excepted from product registration. HSA keeps a public list of notified Class 1 CTGTP. HSA: Class 1 CTGTP notification

A notification is not an HSA approval or evaluation of the product’s performance.

Indonesia Regulatory record

RegulatorMinistry of Health of the Republic of Indonesia (Kemenkes RI)
RegistrationIzin edar AKL 20602420387
ClassificationNon-electromedical, sterile. Class C. Dental prosthetic equipment; bone grafting material
Pack registeredBox of 1 strip (4 × 0.25 cc)
RegistrantPT Global Sarana Trading, Bekasi
Valid until14 May 2027

Product documents

From the catalogue: “Regulatory clearance or licensing status may vary across different countries.”

Report

Report an adverse event

The AmGraft® IFU says that adverse outcomes potentially attributable to the product must be promptly reported to Ventas Bio Pte Ltd or your distributor, and to your country’s competent authority. Please report to both.

1. The manufacturer or the distributor

Ventas Bio Pte Ltd (manufacturer)[email protected] · +65 6871 4004
2 Tukang Innovation Grove #07-02, Singapore 618305
Santé Maison (distributor)[email protected] · +65 6240 6900
If you report to us, we forward the report to Ventas Bio.

Where you can, include the product name, the lot number and expiry date from the label, the date of the procedure and a description of the event.

2. The competent authority

Companies that supply CTGTP in Singapore must report serious adverse events to HSA no later than 15 calendar days after becoming aware of them. HSA: Adverse event reporting of CTGTP